WSG Westdeutsche Studiengruppe
WSG Westdeutsche Studiengruppe is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)
Sponsor Medica Scientia Innovation Research S.L.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Patient-Centered Study of Trastuzumab Deruxtecan (T-DXd) in First-Line HER2-Positive Metastatic Breast Cancer with Proactive Toxicity Management Reflecting Real-World Clinical Practice / TOP-REAL Trial
Sponsor Solti Group
- Start (EU)
- Latest update
- Estimated end
- Not reported
ABCSG 63 / ERIKA: Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer: An open-label, two-arm, randomized, phase II study of elacestrant plus ribociclib vs. AI (plus GnRH agonist in pre-/perimenopausal women and men) plus ribociclib as neoadjuvant therapy for endocrine-responsive HER2-negative early breast cancer
Sponsor Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group
- Start (EU)
- Latest update
- Estimated end
- Not reported
An open-label randomised, phase II trial of Datopotamab deruxtecan plus Durvalumab versus Datopotamab deruxtecan in patients with PDL1-negative metastatic triple-negative breast cancer
Sponsor Queen Mary University Of London
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for WSG Westdeutsche Studiengruppe?
The 2026-10-09 snapshot links WSG Westdeutsche Studiengruppe to 4 distinct CTIS trials. Recorded services include Clinical monitoring, Investigator recruitment, Local Partner, Project management, among 6 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for WSG Westdeutsche Studiengruppe?
The most frequently recorded therapeutic areas are Solid Tumor Oncology. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to WSG Westdeutsche Studiengruppe conducted?
The linked trials record locations in 5 countries, including Germany, Spain, Austria, France, Italy. These are trial locations, not confirmed office locations or countries where WSG Westdeutsche Studiengruppe delivered services.
What can this page tell me about WSG Westdeutsche Studiengruppe's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under WSG Westdeutsche Studiengruppe. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- WSG Westdeutsche Studiengruppe GmbH